Market Signal Briefing

Anthony Scaramucci, the founder and managing partner of SkyBridge Capital, hailed Solana (CRYPTO: SOL) as the “fastest-growing” ecosystem on earth on Saturday.

Scaramucci’s New Book On SolanaScaramucci took to X to promote his new book “Solana Rising: Investing in the Fast Lane of Crypto,” in which he advocates for the popular layer-1 blockchain.

“Solana is the fastest-growing app ecosystem on earth — and nobody saw it coming. ‘Solana Rising’ spills the receipts,” the popular cryptocurrency advocate said.

See Also: $100,000 Blockchain Gaming Esports Tournament: Crypto Startups Making Big Bets As Blockchain-Based Assets Make Rebound

Solana’s Long-Term PotentialScaramucci’s post follows his previous statements about Solana’s potential to become the industry standard for tokenized assets. He has consistently advocated for the blockchain, citing the unique technical properties that make it a leading platform for developers.

Solana currently has a total value locked of $8.41 billion, according to DeFiLlama, only trailing Ethereum (CRYPTO: ETH), making it one of the biggest blockchains for decentralized finance.

Additionally, Chainspect data shows Solana has the most active developers across all blockchains.

Scaramucci said Solana is a core position for SkyBridge and for his personal holdings. He said the firm invested early, similar to its Bitcoin (CRYPTO: BTC) strategy five years ago. 

Scaramucci previously authored a book called "The Little Book of Bitcoin," aimed at helping readers grasp the financial significance of digital assets.

Price Action: At the time of writing, SOL was exchanging hands at $134.13, up 0.56% in the last 24 hours, according to data from Benzinga Pro. The coin has plunged 30% year-to-date.

Read Next: 

Trump’s Bitcoin, ETH, XRP Reserve Isn’t Happening Anymore In 2025, Polymarket Traders Predict
Photo courtesy: Al Teich / Shutterstock.com

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Crypto Pivots in Play: Bitcoin, Ether at Critical Junctures, XRP Probes $2 SupportETH mirrors BTC's counter-trend consolidation as XRP probes key $2 support and SOL remains directionless Dec 8, 2025, 4:47 a.m.

This is a technical analysis post by CoinDesk analyst and Chartered Market Technician Omkar Godbole.

Bitcoin BTC$91,235.39 continues to trade within a counter-trend rising channel on the hourly chart that sits inside a larger descending trend, leaving price action finely poised.

STORY CONTINUES BELOW

A clean break above $96,500 would be technically bullish, as this level marks the confluence of the channel top and the broader bearish trendline, and would argue for a revival of the medium-term uptrend. The weekly chart supports this scenario, with the repeated defense of the 100-week simple moving average, signaling downside exhaustion and growing risk of a bullish reversal.

BTC's hourly and weekly charts. (CoinDesk)

However, the structure also leaves room for renewed weakness if buyers fail to force confirmation.

A downside break from the hourly counter-trend channel would validate the downtrend line and open the way for another test of the $80,000 area, where the market previously found support.

Ether's technical structure mirrors BTC's, trading within a counter-trend rising channel on the hourly chart amid a broader descending trend. A decisive break above $3,200, the channel resistance, would confirm bullish revival, exposing $3,620, the Nov. 10 lower high resistance.

ETH's hourly chart. (TradingView)

Downside risks persist if sellers invalidate the counter-trend channel. A break below would reinforce the larger downtrend, opening recent lows near $2,630 as initial support ahead of deeper correction.

Overall, $3,200 remains the pivotal level to watch.

XRPPayments-focused XRP is testing the critical $2 support line once again, which has repeatedly signaled seller exhaustion this year through long-tailed weekly candles. The momentum looks bearish as evidenced by the sharply declining 5- and 10-week SMAs confirm bearish momentum.

XRP's weekly chart. (TradingView)

A breakdown below this level risks triggering holder capitulation, exposing $1.63, the 61.8% Fibonacci retracement of the 2024-2025 rally, as next major support.

Conversely, consecutive daily closes above $2.30 would invalidate the bearish lower highs pattern and signal bullish revival. $2 remains the key pivot in this symmetrical setup.

SOLSolana SOL$134.93 continues exhibiting range-bound indecision, trading within a sideways channel defined by $145 upper resistance and $120 lower support, with current levels near $134.

The lack of directional momentum persists, leaving the next significant move contingent on a clear breach of this consolidation range.​ Bullish resolution of the range would create room for a move to $160 and higher via measured move analysis. A downside break would extend the broader downtrend.

SOL's hourly chart. (TradingView)

AI Disclaimer: Parts of this article were generated with the assistance from AI tools and reviewed by our editorial team to ensure accuracy and adherence to our standards. For more information, see CoinDesk's full AI Policy.

More For You

Protocol Research: GoPlus Security

Nov 14, 2025

What to know:

As of October 2025, GoPlus has generated $4.7M in total revenue across its product lines. The GoPlus App is the primary revenue driver, contributing $2.5M (approx. 53%), followed by the SafeToken Protocol at $1.7M.GoPlus Intelligence's Token Security API averaged 717 million monthly calls year-to-date in 2025 , with a peak of nearly 1 billion calls in February 2025. Total blockchain-level requests, including transaction simulations, averaged an additional 350 million per month.Since its January 2025 launch , the $GPS token has registered over $5B in total spot volume and $10B in derivatives volume in 2025. Monthly spot volume peaked in March 2025 at over $1.1B , while derivatives volume peaked the same month at over $4B.View Full Report

More For You

Bitcoin’s Deep Correction Sets Stage for December Rebound, Says K33 Research

14 hours ago

K33 Research says market fear is outweighing fundamentals as bitcoin nears key levels. December could offer an entry point for bold investors.

What to know:

K33 Research says bitcoin’s steep correction shows signs of bottoming, with December potentially marking a turning point.The firm has argued that the market is overreacting to long-term risks while ignoring near-term signals of strength, like low leverage and solid support levels.With likely policy shifts ahead and cautious positioning in futures, K33 sees more upside potential than risk of another major collapse.Read full story

PENGU price surged by 8% as the Pudgy Penguins x Care Bears Partnership initiated the bullish momentum

Bitcoin's projected climb gained fresh momentum as Ripple CEO Brad Garlinghouse and Binance CEO Richard Teng voiced bullish long-term expectations, reinforcing broad confidence that the asset could push higher amid strengthening market structure and growing institutional participation.

XRP is approaching a crucial technical zone that historically increases the likelihood of a price rebound, as the asset continues to defend the $2.00–$2.10 support range. Despite months of controlled selling and a persistent downward channel, the market structure now signals weakening bearish momentum right as buyers typically attempt a counter-move. Each retest of the channel’s lower boundary has produced a reaction, showing that sellers are struggling to push the price further down.

One of the strongest bullish signals is the absence of new lows. Over recent weeks, XRP has repeatedly returned to the same support level without breaking below it. This pattern indicates that selling pressure is no longer intensifying and that supply is not rising at lower price zones — a common precursor to short-term reversals. Supporting this outlook, volume data shows decreasing selling spikes and a transition into a compression phase, where volatility contracts before a potential breakout.

Momentum indicators reinforce this setup. The RSI hovering in the low 40s suggests ongoing pressure without capitulation, creating room for upside movement without triggering overbought conditions. Historically, XRP often sees notable relief rallies from similar positions within long-term descending channels.

If buyers regain control, the first resistance zone lies between $2.16 and $2.20, aligning with the 20-day moving average. A stronger push could carry the price toward the 50-day MA at $2.28 — a level that has consistently acted as a rejection point. Should XRP break above this barrier, a move toward the mid-channel range at $2.40–$2.45 becomes increasingly likely, marking the first meaningful improvement in medium-term sentiment.

This developing structure positions XRP for a potentially significant bounce if current support continues to hold and market momentum shifts.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

Bulls eye a move past $3.2, but MYX's mixed timeframes leave traders watching for clearer conviction.

Leading cryptocurrencies rallied, while stock futures were little changed on Sunday, as investors geared up for the Federal Reserve’s interest rate announcement.

CryptocurrencyGains +/-Price (Recorded at 8:25 p.m. ET)Bitcoin (CRYPTO: BTC)+1.68%$90,990.60Ethereum (CRYPTO: ETH)
               +1.34%$3,088.63XRP (CRYPTO: XRP)                         +0.92%$2.05Solana (CRYPTO: SOL)                         +0.03%$132.69Dogecoin (CRYPTO: DOGE)                         -0.59%$0.1392End Of The Week RallyBitcoin gained momentum overnight on Sunday after a calm weekend, with trading volume jumping 29.4% over the last 24 hours. The apex cryptocurrency was on course to finish the week in the green.

Ethereum also rallied, hitting an intraday high of $3,148.77, while trading volume for the second-largest cryptocurrency nearly doubled. 

Cryptocurrency liquidations reached $437 million over the last 24 hours, according to Coinglass, with long liquidations amounting to over $280 million.

Bitcoin's open interest rose 2.22% in the last 24 hours. An increase in open interest, coming alongside an uptick in spot price, typically indicates new money flowing into the derivatives market.

The market sentiment slipped back into the "Extreme Fear" zone, according to the Crypto Fear & Greed Index. 

Top Gainers (24 Hours) 

Cryptocurrency (Market Cap>$100 M)Gains +/-Price (Recorded at 8:25 p.m. ET)Wrapped Pulse (SN )   +25.44%$0.00002111Pieverse (PIEVERSE)    
               +25.42%$0.7686Audiera (BEAT )          +24.28%$1.85The global cryptocurrency market capitalization stood at $3.07 trillion, following a rise of 0.74% in the last 24 hours.

Stock Futures Little ChangedStock futures remained largely flat Sunday evening. The Dow Jones Industrial Average Futures fell 5 points, or 0.01%, as of 7:49 p.m. EDT.  Futures tied to the S&P 500 gained 0.02%, while Nasdaq 100 Futures added 0.03%.

The market is coming off a winning week, with the S&P 500 and the Nasdaq Composite rising 0.61% and 1.39%, respectively, boosted by high expectations of a rate cut at the Federal Reserve meeting later this week. 

The CME FedWatch tool now shows an 88% chance of a 25-basis-point cut.

The Bureau of Economic Analysis published the delayed September inflation data on Friday, with the core Personal Consumption Expenditure index coming in softer than expected.

Best Price To Accumulate ETH?Popular cryptocurrency analyst and trader Michaël van de Poppe described Bitcoin's Sunday uptick as a "great sign" but warned against the CME futures gap created at $89,400

CME gaps are the differences in price between the closing price on a given trading day and the opening price on the following trading day on a Bitcoin futures chart. 

"Although it’s a great sign that markets are waking up and we’re seeing this momentum, I think it’s not bad to be a little aware of the potential CME gap correction on Monday/Tuesday," Van De Poppe said.

"Other than that, let’s break this resistance zone and get to $100,000. Sentiment will change when these moves happen," the analyst added.

Ali Martinez, another widely followed cryptocurrency commentator, identified $1,800 as "one of the best accumulation zones" before a bull run toward $10,000.

Read Next:    

Peter Schiff ‘So Close’ To Accepting Bitcoin’s Potential, Says Crypto Billionaire Changpeng Zhao, But The Economist Remains ‘Stubborn’
Photo Courtesy: Sodel Vladyslav on Shutterstock.com

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Bitcoin price started a fresh increase above $90,500. BTC is now consolidating gains and might attempt an upside break above $91,650.

Bitcoin started a fresh increase above the $90,500 zone.
The price is trading above $91,000 and the 100 hourly Simple moving average.
There was a break above a key bearish trend line with resistance at $90,000 on the hourly chart of the BTC/USD pair (data feed from Kraken).
The pair might continue to move up if it settles above the $91,650 zone.

Bitcoin Price Faces Resistance
Bitcoin price managed to stay above the $90,500 zone and started a fresh increase. BTC gained strength for a move above the $91,500 and $92,500 levels.

There was a clear move above the $93,000 resistance. A high was formed at $94,050 and the price recently corrected some gains. There was a drop below the 50% Fib retracement level of the upward move from the $83,871 swing low to the $94,050 high.

However, the bulls were active near the $87,800 support and the 61.8% Fib retracement level of the upward move from the $83,871 swing low to the $94,050 high. The price is again rising above $90,000.

There was a break above a key bearish trend line with resistance at $90,000 on the hourly chart of the BTC/USD pair. Bitcoin is now trading above $91,000 and the 100 hourly Simple moving average.

Source: BTCUSD on TradingView.com
If the bulls remain in action, the price could attempt another increase. Immediate resistance is near the $91,650 level. The first key resistance is near the $92,000 level. The next resistance could be $93,000. A close above the $93,000 resistance might send the price further higher. In the stated case, the price could rise and test the $95,000 resistance. Any more gains might send the price toward the $95,500 level. The next barrier for the bulls could be $96,200 and $96,450.

Another Decline In BTC?
If Bitcoin fails to rise above the $91,650 resistance zone, it could start another decline. Immediate support is near the $90,000 level. The first major support is near the $89,500 level.

The next support is now near the $87,800 zone. Any more losses might send the price toward the $87,250 support in the near term. The main support sits at $86,500, below which BTC might accelerate lower in the near term.

Technical indicators:

Hourly MACD – The MACD is now gaining pace in the bullish zone.

Hourly RSI (Relative Strength Index) – The RSI for BTC/USD is now above the 50 level.

Major Support Levels – $90,000, followed by $89,500.

Major Resistance Levels – $91,650 and $92,000.

XRPUSD – Daily Chart – 081225 – Vanguard Impact
Bullish Medium-Term Outlook Intact
Expectations of a Fed rate cut and the potential for further easing in H1 2026 suggest a bullish week ahead. However, there are several key events that may act as tailwinds for XRP, including:

Widening investor access to spot ETFs.
The progress of crypto-friendly legislation, including the Market Structure Bill.
December and March Fed rate cut expectations.

In my view, these scenarios support a near-term (1-4 weeks) move to $2.35 and a medium-term (4-8 weeks) climb toward $2.5.

Downside Risks to Bullish Outlook
While the short- to medium-term outlook is bullish, several events could derail the outlook. These include:

The Bank of Japan triggers a yen carry trade unwind, hitting XRP and the broader crypto market.
The MSCI delists digital asset treasury companies (DATs). Delistings could dampen demand for XRP as a treasury reserve asset.
US Senate challenges the Market Structure Bill.
OCC rejects Bitcoin’s application for a US-chartered banking license.
XRP-spot ETFs report heavy outflows.

These events would likely drag XRP below $2, bringing the November low of $1.82 into play before a longer-term return to $3.

However, in my opinion, robust demand for XRP-spot ETFs, expectations of crypto-friendly regulations, an expanding investor base, and a dovish Fed will likely support a move toward $3.

In summary, the short-term outlook remains cautiously bullish, while the medium- to longer-term outlook is constructive.

Financial Analysis
Technical Outlook: EMAs Signal Caution
XRP rose 0.68% on Sunday, December 7, reversing the previous day’s 0.22% to close at $2.0456. The token underperformed the broader crypto market, which gained 0.85%.

Despite snapping a three-day losing streak, XRP remained below the 50-day and 200-day Exponential Moving Averages (EMAs), indicating a bearish bias. However, fundamentals are shifting from the technical trend, supporting a bullish outlook.

Key technical levels to watch include:

Support levels: $2, $1.9112, and $1.8239
50-day EMA resistance: $2.2757.
200-day EMA resistance: $2.4785.
Resistance levels: $2.2, $2.35, $2.5, $2.62, $2.8, $3.0, and $3.66.

Holding above the $2.0 psychological support level would bring the 50-day EMA into play. A sustained break above the 50-day EMA would pave the way to the $2.35 resistance level. Crucially, a break above the 50-day EMA would signal a near-term bullish trend reversal. A bullish trend reversal would support a medium-term (4-8 weeks) rise to the 200-day EMA and the $2.5 level.

The decentralized, AI-focused network Bittensor is set for its first halving event on Dec. 14, marking the end of its inaugural four-year cycle. This pivotal event will halve the daily issuance of its native TAO token from 7,200 to 3,600.

Bittensor operates as an open network at the intersection of AI and crypto, allowing users to freely contribute intelligence to improve AI systems. 

The network has subnets that are each dedicated to a specific AI task, and distributes TAO as incentives based on the utility of user input. There are currently 129 active subnets that offer a variety of AI-led services including compute, data storage, AI agents, and deepfake detection.

The network's halving is poised to increase the scarcity of TAO by reducing the token emissions distributed among network participants.

"Bitcoin's history shows that reduced supply can enhance network value despite smaller rewards, as its network security and market value have strengthened through four successive halvings," said Grayscale Research Analyst Will Ogden Moore. "Similarly, Bittensor's first halving marks a key milestone in the network's maturation as it progresses toward its 21 million token supply cap."

Moore said Bittensor is currently seeing strong adoption and rising institutional interest. The Grayscale analyst pointed to the February launch of dynamic TAO (dTAO) as a major achievement for Bittensor. This mechanism made subnets directly investible, leading to a sharp expansion in the total market capitalization of those subnets, Moore said.

Since the launch of dTAO, institutional investors such as Yuma Asset Management and Stillcore Capital, have launched funds investing in Bittensor's top subnets. Moreover, three public companies have established dedicated TAO treasuries. TAO Synergies, the leading firm, currently holds about $12 million worth of the token.

"The early success of certain subnet-based applications and an increase in institutional capital in the Bittensor ecosystem, combined with the forthcoming TAO supply halving, could be a positive catalyst for price, in our view," Moore wrote. 

According to The Block's crypto price page, TAO is up 0.5% in the past 24 hours to trade at $282.31. It is down 28.4% in the past month.

Disclaimer: The Block is an independent media outlet that delivers news, research, and data. As of November 2023, Foresight Ventures is a majority investor of The Block. Foresight Ventures invests in other companies in the crypto space. Crypto exchange Bitget is an anchor LP for Foresight Ventures. The Block continues to operate independently to deliver objective, impactful, and timely information about the crypto industry. Here are our current financial disclosures.

© 2025 The Block. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

In brief
Bitcoin rose to about $91,950 on Sunday, extending its rebound from the month’s $85,000 trough.
Traders remain cautious after October’s $19 billion leverage wipeout, with market makers slow to return, Decrypt was told.
Expectations for a rate cut strengthened as jobless-claim forecasts climb and the Fed concludes QT.
Bitcoin inched higher on Sunday, reclaiming the $90,000 price tag as traders await the Federal Reserve’s last interest-rate decision for the year and this week’s latest jobs data.

The world’s largest crypto is up 1.8% on the day to $91,950 and has since recovered from its early December lows near $85,000, according to CoinGecko data. The asset is up 5.3% for the month.

Bitcoin has been caught in a narrow trading range following the $19 billion leverage wipeout in early October, amid fears of sticky inflation that could complicate the Fed’s path to future rate cuts.

"Shifting rate expectations ripple through crypto funding markets in Asia far more quickly than traditional asset classes," Michael Wu, CEO of Amber Group, told Decrypt. 

"We’re seeing funding spreads and borrow costs move in lockstep with global rate guidance," Wu added. "This drives a critical re-evaluation of treasury strategies; many desks are diversifying liquidity across CeFi and DeFi venues to isolate against volatility and optimize opportunities as macro cycles accelerate."

Services inflation, meanwhile, has cooled from last year’s peaks but remains firmer than goods prices, with shelter still running above the Fed’s target.

That uneven progress has complicated the Fed’s disinflation plan and kept traders wary of how far and how quickly rate cuts might unfold, including the central bank's final decision for the year on Wednesday.

With that setup weighing on investor sentiment, gold and silver have soared, while Bitcoin lingers as the digital asset remains more sensitive to macro shocks than U.S. equities.

“Low liquidity is still an issue for the market,” Ryan McMillin, chief investment officer at Merkle Tree Capital, told Decrypt. “Since the October 10 event, order books were wiped out, and market makers are shy to jump back in in size.”

Economists are forecasting a spike in initial jobless claims on Thursday of 30,000, up from the previous reported figure of 191,000, MarketWatch data shows.

That could bolster the Fed’s case for a cut now that economic data releases have returned to schedule following delays caused by the longest government shutdown in U.S. history.

A cut to the Fed’s funds rate is typically seen as a boon for risk assets, as borrowing becomes cheaper, potentially leading to a rally in risk assets, including crypto, or so the thinking goes.

With economic data now flowing normally again, McMillin said “a cut is not just about certain,” adding that with the Fed ending quantitative tightening on December 1, “the market is set to rally.”

“The rate cut might be the catalyst for that to start,” he said.

Daily Debrief NewsletterStart every day with the top news stories right now, plus original features, a podcast, videos and more.

Alphabet stock is soaring, and it could go even higher in 2026.

Alphabet (GOOG +1.16%)(GOOGL +1.09%) has made an impressive turnaround this year. In April, its share price sank as low as $141. It's currently sitting above $300 and is up nearly 69% year to date (as of Dec. 5).

There's understandable trepidation about investing in stocks after this rate of growth. But the parent company of Google remains an excellent investment, and there's one reason in particular it could continue to do well.

Image source: Alphabet.

Alphabet's AI stack gives it a significant edge
Artificial intelligence (AI) has been a major growth driver for tech companies, including Alphabet. The key differentiator for Alphabet is its full-stack approach. Other AI companies rely on partnerships, typically with Nvidia for graphics processing units (GPUs) and OpenAI, the developer of ChatGPT, for AI models.

Alphabet, on the other hand, develops its own custom Tensor Processing Units (TPUs) to train AI models. It has its own software framework, research lab, and large language model (LLM), Gemini. Gemini 3, which was released on Nov. 18, has received rave reviews so far and been part of Alphabet's recent success. Because Alphabet can do everything in-house, it isn't reliant on other companies for its AI development.

Today's Change

(

1.09

%) $

3.45

Current Price

$

321.07

This vertical integration allows Alphabet to reduce the notoriously high costs involved with AI computing. It's also a revenue driver, as Alphabet can sell its AI products and services to other companies. For a recent example, Bloomberg has reported that Meta Platforms is considering purchasing Alphabet's TPUs for its data centers instead of Nvidia GPUs.

Alphabet stock was a bargain earlier this year. Although it's now trading at a much higher valuation, this is still one of the best tech companies and one that's well-positioned to capitalize on the growth of AI.

Lyle Daly has positions in Alphabet, Meta Platforms, and Nvidia. The Motley Fool has positions in and recommends Alphabet, Meta Platforms, and Nvidia. The Motley Fool has a disclosure policy.

HomeIndustriesMediaPublished: Dec. 7, 2025 at 8:54 p.m. ET

President Donald Trump and first lady Melania Trump arrive for the 48th Kennedy Center Honors gala Sunday. Photo: AFP via Getty ImagesComments by President Donald Trump on Sunday raised an antitrust red flag over Netflix’s $72 billion deal to acquire Warner Bros. Discovery.

Speaking to reporters before an event at the Kennedy Center in Washington, Trump said a combination between the largest and fourth-largest streaming services in the U.S. “could be a problem.”

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

SINGAPORE, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Digital Realty (NYSE: DLR), the largest global provider of cloud- and carrier-neutral data center, colocation, and interconnection solutions and an Oracle Partner, today announced it will offer connectivity to an Oracle Cloud Infrastructure (OCI) FastConnect point-of-presence (PoP) within the Oracle Cloud Singapore West Region. In addition to the new connectivity, Digital Realty is also making an Oracle Solution Center available in Singapore through its global data center platform, PlatformDIGITAL®. The Oracle Solution Center will provide customers with a secure environment to design, test, and validate hybrid and AI architectures. It is the first in Singapore and reinforces the country’s role as a strategic regional hub for digital infrastructure and AI transformation.

The new connectivity will provide customers in southeast Asia with low-latency access and improved redundancy by adding a second on-ramp to OCI in the region. It will also enable customers to support hybrid, AI-enabled, and cloud-adjacent workloads more effectively. With OCI, customers benefit from best-in-class security, consistent high performance, simple predictable pricing, and the tools and expertise needed to bring enterprise workloads to the cloud quickly and efficiently.

“The launch of OCI FastConnect in Singapore marks an important step in our continued partnership with Oracle, and ongoing commitment to helping customers deploy cloud and AI workloads with speed and confidence,” said Serene Nah, Managing Director and Head of Asia Pacific, Digital Realty. “Together with Oracle, we’re enabling enterprises to seamlessly connect to the cloud, scale AI innovation, and future-proof their digital infrastructure in Asia Pacific and around the world.”

“Customers require high throughput, private, and secure connectivity between their on-premises environment and cloud to support their business critical and evolving AI application needs. With OCI FastConnect service and Digital Realty’s global footprint, customers can provision these dedicated high throughput private connections easily and scale to meet their growing business demands,” said Chris Chelliah, Senior Vice President, Technology and Customer Strategy, Oracle Japan & Asia Pacific.

OCI’s extensive network of more than 110 FastConnect global and regional partners offer customers dedicated connectivity to Oracle Cloud Regions and OCI services – providing customers with the best options anywhere in the world. 

Earlier this year, Digital Realty also participated as an ecosystem partner at the launch of the Oracle AI Centre of Excellence in Singapore, which is designed to help organizations train teams, experiment in secure cloud environments, and provide the knowledge needed to transform critical business operations.

Additional Resources

Learn more about Oracle Cloud Infrastructure (OCI) FastConnect hereLearn more about PlatformDIGITAL® hereLearn more about ServiceFabric® hereLearn more about Digital Realty’s data centers in Singapore here About Digital Realty
Digital Realty brings companies and data together by delivering the full spectrum of data center, colocation, and interconnection solutions. PlatformDIGITAL®, the company’s global data center platform, provides customers with a secure data meeting place and a proven Pervasive Datacenter Architecture (PDx®) solution methodology for powering innovation, from cloud and digital transformation to emerging technologies like artificial intelligence (AI), and efficiently managing Data Gravity challenges. Digital Realty gives its customers access to the connected data communities that matter to them with a global data center footprint of 300+ facilities in 50+ metros across 25+ countries on six continents. To learn more about Digital Realty, please visit digitalrealty.com or follow us on LinkedIn and X.

About Oracle’s Partner Program
Oracle’s partner program helps Oracle and its partners drive joint customer success and business momentum. The newly enhanced program provides partners with choice and flexibility, offering several program pathways and a robust range of foundational benefits spanning training and enablement, go-to-market collaboration, technical accelerators, and success support. To learn more, visit https://www.oracle.com/partner/.
Trademark
Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing.

Safe Harbor Statement
This press release contains forward-looking statements which are based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially, including statements related to the company's partnership with Oracle, Oracle Cloud Infrastructure, ServiceFabric®, expected benefits, the company's strategy, customer demand, artificial intelligence and the Asia Pacific market. For a list and description of risks and uncertainties, see the reports and other filings by the company with the U.S. Securities and Exchange Commission. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Nvidia's GPUs recently took a test.

Nvidia (NVDA 0.53%) has built an artificial intelligence (AI) chip empire over the past several years. Originally known for serving the video game market with chips, Nvidia pivoted to focus on AI, and that has emerged as its key business. This has proven to be a smart move as it's fueled enormous revenue growth for the company -- for example, annual revenue has increased by 2,500% over the past decade.

The tech company's entry into the market ahead of others secured its leadership, and its ongoing innovation has kept that going. Still, some investors have worried about Nvidia facing competition in the coming years, from other chip designers as well as its own customers -- some, such as Amazon, have developed their own chips that they use and sell along with those of other chip companies.

Should you worry about Nvidia's AI market leadership moving forward? The following 21 words from Nvidia chief Jensen Huang offer us a strikingly clear answer.

Image source: Getty Images.

An early bet on AI
Before diving in, though, let's take a quick look at the Nvidia success story and the growth of competition. As mentioned, Nvidia placed an early bet on the potential of the AI chip market by developing graphics processing units (GPUs) suited to the needs of this technology. And Nvidia has broadened its offerings to include a full range of products and services. All of this has resulted in revenue soaring to record levels; for example, revenue reached more than $130 billion in the latest fiscal year. And Nvidia also has reached high profitability on sales, generally maintaining gross margin above 70% in recent quarters.

But, as mentioned, Nvidia isn't the only game in town when it comes to AI chips. It faces competition from chip designers such as Advanced Micro Devices and Broadcom, as well as its own customers, such as Amazon. The company's Amazon Web Services (AWS) unit has developed its own line of chips, offering an option to cost-conscious customers. And Alphabet, owner of Google Cloud, also is a Nvidia customer that's developed its own chips. These players, in recent earnings reports, each have spoken of high demand from AI customers for these products.

So, it's clear that competition could be something investors might worry about as this AI story develops. Before we get to the comment from Jensen Huang, here's one important note about the use of the company's AI chips.

Today's Change

(

-0.53

%) $

-0.97

Current Price

$

182.41

Training LLMs
Initially, Nvidia's GPUs were used to power the training of large language models (LLMs), so that they would gain the information or knowledge to go on and answer questions or solve problems. This still is the case, but today and moving forward, the company's high-powered GPUs also serve as the power LLMs need to "think" and "reason." This is called the inference process, and Nvidia is betting that it will be a major growth area for AI chips.

Nvidia's Blackwell GPUs, in a recent test of their strength in inferencing, delivered the strongest performance and lowest total cost of ownership across models and use cases. Applied to the DeepSeek R1 model, Blackwell generated a 10 times higher performance per watt and 10 times lower cost per token compared to Nvidia's Hopper-driven chips. (Tokens are bits of data handled during training and inferencing.) These tests are designed by MLCommons, a consortium of AI experts.

Words from Jensen Huang
Jensen Huang's message regarding that performance is clear:

"It's gonna take a long time before somebody is able to take that on," Huang said during the company's earnings call last month. "And our leadership there is surely multiyear."

So, Nvidia continues to offer AI customers the most powerful compute, and that matters to many players that aim to reach their goals fast -- and gain in cost savings and efficiency over time. Of course, there is plenty of room in the market for Nvidia competitors to carve out share -- certain customers may not require the most powerful GPU, and even major customers might prefer other chips, such as Broadcom's custom AI chips, for certain jobs.

But Nvidia chips continue to stand out as the most powerful option, and the company's commitment to innovation should keep that going. It's also important to note that inferencing could be big, since it involves the powering of LLMs as they carry out their tasks.

Let's get back to our question: Should you worry about Nvidia's market dominance? Huang's recent comment leads us to a strikingly clear answer -- "no." The tech giant remains on track to dominate the market and win in the promising area of inferencing over the long term.

By

:

Published: Dec 8, 2025, 02:10 GMT+00:00

Gold and silver remain supported by expectations of a Fed rate cut, strong central bank demand, and bullish technical patterns, with gold targeting $4,380 and silver aiming for $62.

Gold (XAU) is trading higher near $4,205 in early Monday trading, as markets widely expect the Federal Reserve to cut interest rates at its upcoming meeting. This policy shift supports investor interest in the metal, especially in the face of a cooling labour market. The expectations of easier monetary policy continue to provide a bullish backdrop for gold.

Moreover, recent data show that inflation remains above the Fed’s 2% target. However, slowing job growth has increased pressure for a rate cut. A 25-basis-point reduction is now largely factored into the price. The lower rates weaken the US dollar and Treasury yields, both of which benefit gold prices. If the Fed confirms this dovish stance on Wednesday, gold may extend its gains toward the $4,380 resistance zone.

On the other hand, central bank demand continues to support gold’s long-term bullish trend. The People’s Bank of China added to its gold reserves for the 13th consecutive month, lifting total holdings to over 74 million troy ounces. This consistent buying reinforces gold’s role as a strategic reserve asset in times of currency uncertainty or geopolitical tension. Sustained demand from global central banks provides a floor for gold prices.

However, improved US consumer sentiment poses a risk to gold in the near term. The University of Michigan consumer sentiment increased to 53.3, beating expectations and signalling some resilience in the US economy. If the dollar strengthens on the back of better economic data, gold could face resistance. A stronger dollar makes gold more expensive for foreign buyers, potentially limiting upside momentum in the days ahead.

Gold Technical Analysis
XAUUSD Daily Chart – Bullish Consolidation
The daily chart for spot gold shows that the price is consolidating within an ascending broadening wedge pattern. It has broken out of the triangle and is now consolidating around the $4,200 area.

A break above $4,260 could trigger a move toward the $4,380 resistance level. Furthermore, a breakout above $4,380 would likely initiate a strong surge in gold prices. The sustained consolidation above the $4,000 region signals strong support in the gold market. This has been followed by the formation of a bullish structure, indicating growing positive momentum.

XAUUSD 4-Hour Chart – Positive Price Development
The 4-hour chart for spot gold shows that the price is consolidating above a rising trendline. Notably, the price has formed a double bottom pattern on this line multiple times. Each time, the price tests the support level, a rebound follows. Therefore, a break above $4,260 would be a bullish signal and could push the price toward the $4,380 level.

Silver Technical Analysis
XAGUSD Daily Chart – Strong Bullish Momentum
The daily chart for spot silver (XAG) shows a strong bullish formation confirmed by a cup-and-handle pattern. The breakout above $54.50 has solidified a bullish structure. A move above $59.33 would likely push prices higher toward the $62 level. Furthermore, the strong upward momentum, supported by the rising 50-day and 200-day SMAs, indicates a firmly bullish trend in the silver market.

XAGUSD 4-Hour Chart – Positive Price Development
The 4-hour chart for spot silver shows that the price has formed a strong bullish pattern. An inverted head-and-shoulders formation is developing above the $45.80 level. A breakout above $54.50 pushed the price to a new record high at $59.33.

Following this high, silver is now consolidating within a wedge pattern, which signals short-term volatility. The upcoming Federal Reserve meeting on December 10 is likely to act as a catalyst for the next major move in the silver market.

US Dollar Index Technical Analysis
US Dollar Daily – Negative Momentum
The daily chart for the USD Index shows that it is trading below the 99 level and remains weak below the 200-day SMA. The loss of momentum following the failure to break above 100.50 suggests the index is preparing for another move lower.

A break below the 98 level could trigger a sharp decline toward the 96.50 support area. Furthermore, a drop below 96.50 would likely open the door for a deeper move toward the 90 level. To negate this bearish setup, a decisive break above 100.50 is required.

US Dollar 4-Hour Chart – Double Top Pattern
The 4-hour chart for the US Dollar Index shows that the index is consolidating below the 99 level after forming a double top at the 100.50 level. This pattern suggests further downside in the short term. However, the broader trend remains in a consolidation phase between the 96.50 and 100.50 levels. A breakout from this range will determine the next major move in the US Dollar Index.

Related Articles

Oil News: Traders Eye 52-Week MA on Supply Risks and Fed CutsNatural Gas News: Bulls Eye $5.992—But Will Mid-December Warmth Spoil the Rally?Silver (XAG) Forecast: Price Prediction Points Higher if Fed Confirms 2026 Rate Cuts

Muhammad Umair is a finance MBA and engineering PhD. As a seasoned financial analyst specializing in currencies and precious metals, he combines his multidisciplinary academic background to deliver a data-driven, contrarian perspective. As founder of Gold Predictors, he leads a team providing advanced market analytics, quantitative research, and refined precious metals trading strategies.

Important DisclaimersFXEmpire is owned and operated by Empire Media Network LTD., Company Registration Number 514641786, registered at 7 Jabotinsky Road, Ramat Gan 5252007, Israel. The content provided on this website includes general news and publications, our personal analysis and opinions, and materials provided by third parties. This content is intended for educational and research purposes only. It does not constitute, and should not be interpreted as, a recommendation or advice to take any action, including making any investment or purchasing any product. Before making any financial decision, you should conduct your own due diligence, exercise your own discretion, and consult with competent advisors. The content on this website is not personally directed to you, and we do not take into account your individual financial situation or needs. The information contained on this website is not necessarily provided in real time, nor is it guaranteed to be accurate. Prices displayed may be provided by market makers and not by exchanges. Any trading or other financial decision you make is entirely your own responsibility, and you must not rely solely on any information provided through the website. FXEmpire does not provide any warranty regarding the accuracy, completeness, or reliability of any information contained on the website and shall bear no responsibility for any trading losses you may incur as a result of using such information. The website may include advertisements and other promotional content. FXEmpire may receive compensation from third parties in connection with such content. FXEmpire does not endorse, recommend, or assume responsibility for the use of any third-party services or websites. Empire Media Network LTD., its employees, officers, subsidiaries, and affiliates shall not be liable for any loss or damage resulting from your use of the website or reliance on the information provided herein.Risk DisclaimersThis website contains information about cryptocurrencies, contracts for difference (CFDs), and other financial instruments, as well as about brokers, exchanges, and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and involve a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money. FX Empire encourages you to conduct your own research before making any investment decision and to avoid investing in any financial instrument unless you fully understand how it works and the risks involved.

By

PYMNTS
 | 
December 7, 2025

 | 

The chief executive of America’s biggest bank says consumers continue to show resilience.

This is in spite of a cooling job market and ongoing inflation, JPMorgan Chase CEO Jamie Dimon said Sunday (Dec. 7) in an interview with Fox News.

“In the short run, it looks like the American consumer is doing fine, is chugging along, companies are making profits, stock markets are high. That could easily continue,” he said, while also pointing to areas of concern.

“There are little small negatives: Jobs are weakening, but just a little bit, inflation is there and maybe not going down,” Dimon told Fox News’ Maria Bartiromo.

As covered here last week, recent labor reports — spanning government, private sector data and PYMNTS Intelligence findings — demonstrate rising uncertainty among hourly workers, even as these consumers keep spending.

Jobless claims are at their lowest level in three years, though companies are planning more layoffs, and wages for the 60 million workers who make up the Labor Economy have fallen..

Advertisement: Scroll to Continue

PYMNTS Intelligence’s Wage to Wallet Index™ research has found that “these consumers are still shopping, although earnings reports illustrate that they are trading down and concentrating spending in value channels instead of pulling back entirely,” the report added.

The interview also touched on concerns that artificial intelligence (AI) could lead to widespread job cuts. Dimon contended that pressures on the workforce were there even before the technology skyrocketed in popularity.

“Look, I don’t think AI is going to dramatically reduce jobs like unbelievably next year. And for the most part, AI is going to do great stuff for mankind, like tractors did, like fertilizer did, like vaccines did. It’ll save lives,” Dimon said.

Still, he stressed that AI needs to be properly regulated as adoption grows, saying that there were “downsides” to AI the way there is to a variety of products.

“So assuming that the government figured out some way to put guardrails around AI … but it will eliminate jobs,” said Dimon. “It doesn’t mean that people won’t have other jobs.”

Additional research from PYMNTS Intelligence has shown that among people who use generative AI, a third are worried that the technology could threaten people’s jobs.

That concern is most pronounced among members of Generation Z, with 38% of the gen AI users in that age group concerned about the impact on employment. The research shows that Gen Z users tend to have — or are looking for — the kinds of entry-level jobs that the technology can most easily replace.

Sign up to receive our daily newsletter.

We’re always on the lookout for opportunities to partner with innovators and disruptors.

Learn More

EXECUTIVE SUMMARY

VALLAURIX Research, Development & Innovation Centre to expand its existing facilities and capabilities core focus on accelerating development of liquid long-acting drug delivery platformsexisting RD&I teams will advance late-stage development programs without disruption strategic investment supported by the Singaporean Economic Development Board (EDB)five-year funded plan MELBOURNE, Australia and SINGAPORE, Dec. 07, 2025 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced a significant expansion of its VALLAURIX Research, Development and Innovation (RD&I) Centre in Singapore. This strategic five-year investment solidifies the site’s transition into a global hub for developing advanced, long-acting peptide formulations.

Supported by the Singapore Economic Development Board (EDB), the enhanced facility will integrate comprehensive formulation and analytical sciences, focusing on advancing liquid controlled-release drug products designed to optimise therapeutic outcomes for patients. This expansion is a key pillar in CLINUVEL’s strategy of vertical integration and innovation in peptide-based medicine.

A Centre for Delivery Innovation

The VALLAURIX RD&I Centre is dedicated to creating novel pharmaceutical formulations that act as versatile platforms for delivering CLINUVEL’s melanocortins and other therapeutic peptides, with a focus on advanced stage programs.

Since its founding in 2014, the VALLAURIX site has evolved, with the current ISO9001-certified centre opening in 2020 and receiving extensive upgrades in 2022. The new expansion will further broaden its formulation and analytical capabilities, with full commissioning and certification targeted for FY2028.

Commitment to Singapore and Global Growth

CLINUVEL’s global team is spearheading the expansion, with plans to gradually increase specialist headcount in Singapore over the next five years. This growth is made possible through a strengthened economic partnership with the EDB, whose continued investment facilitates the addition of technical expertise and state-of-the-art capabilities.

“CLINUVEL has made a long-term investment in the VALLAURIX team and facility, which has resulted in important advancements in novel drug delivery systems,” said Dr Dennis Wright, CLINUVEL’s Chief Scientific Officer. “Our pipeline now includes platforms designed to optimise therapeutic dosing - delivering minimal, yet highly effective, levels of peptide in flexible formulations to better meet patient needs.

A Future-Focused Facility

The expansion process will ensure that ongoing projects in novel pharmaceutical and PhotoCosmetic formulation continue uninterrupted. Simultaneously, it prepares CLINUVEL to translate its research into tangible advanced therapies.

“We are grateful for the support from EDB and are committed to building a truly unique, bespoke facility in Singapore,” said Mr Lachlan Hay, CLINUVEL’s Chief Operating Officer. “This positions CLINUVEL at the forefront of peptide delivery technologies, enabling us to execute our vision with speed and precision.

“This strategic expansion underscores CLINUVEL’s commitment to leveraging Singapore’s vibrant biotech ecosystem to address complex therapeutic challenges and deliver the next wave of peptide-based medicines,” Mr Hay said.

About CLINUVEL PHARMACEUTICALS LIMITED

CLINUVEL (ASX: CUV; ADR LEVEL I: CLVLY; Börse Frankfurt: UR9) is a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialised populations. As pioneers in photomedicine and the family of melanocortin peptides, CLINUVEL’s research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, assisted DNA repair, repigmentation and acute or life-threatening conditions who lack alternatives.

CLINUVEL’s lead therapy, SCENESSE® (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the world’s first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore, and the USA. For more information, please go to https://www.clinuvel.com.

Authorised for ASX release by the Board of Directors of CLINUVEL PHARMACEUTICALS LTD.

Head of Investor Relations

Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD

Investor Enquiries

https://www.clinuvel.com/investors/contact-us

Forward-Looking Statements

This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL’s management. All statements other than statements of historical or current facts made in this document are forward-looking. We identify forward-looking statements in this document by using words or phrases such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “foresee,” “intend,” “likely,” “may,” “objective,” “potential,” “plan,” “predict,” “project,” “seek,” “should,” “will” and similar words or phrases and their negatives. Forward-looking statements reflect our current expectations and are inherently uncertain. Actual outcomes or results could differ materially for a variety of reasons. Statements may involve a number of known and unknown risks that could cause our future results, performance, or achievements to differ significantly from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialise pharmaceutical products; the COVID-19 pandemic and/or other world, regional or national events affecting the supply chain for a protracted period of time, including our ability to develop, manufacture, market and sell biopharmaceutical and PhotoCosmetic products; competition for our products, especially SCENESSE® (afamelanotide 16mg), CYACÊLLE, PRÉNUMBRA®, NEURACTHEL® or products developed and characterised by us as PhotoCosmetics; our ability to achieve expected safety and efficacy results in a timely manner through our innovative R&D efforts; the effectiveness of our patents and other protections for innovative products, particularly in view of national and regional variations in patent laws; our potential exposure to product liability claims to the extent not covered by insurance; increased government scrutiny in either Australia, the U.S., Europe, the UK, Israel, China, Japan, and/or LATAM regions of our agreements with third parties and suppliers; our exposure to currency fluctuations and restrictions as well as credit risks; the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement; that the Company may incur unexpected delays in the outsourced manufacturing of SCENESSE®, CYACÊLLE, PRÉNUMBRA®, NEURACTHEL® or products developed as PhotoCosmetics which may lead to the Company being unable to launch, supply or serve its commercial markets, special access programs and/or clinical trial programs; any failures to comply with any government payment system (i.e. Medicare, Medicaid, and U.S. Department of Veteran’s Affairs) reporting and payment obligations; uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology, cosmetic and consumer based products; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; our ability to retain or attract key personnel and managerial talent; the impact of broader change within the pharmaceutical industry, cosmetic industry and related industries; potential changes to tax liabilities or legislation; environmental risks; and other factors that have been discussed in our 2025 Annual Report. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation, outside of those required under applicable laws or relevant listing rules of the Australian Securities Exchange, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. More information on preliminary and uncertain forecasts and estimates is available on request, whereby it is stated that past performance is not an indicator of future performance.

Contact:
Tel: +61 3 9660 4900
Fax: +61 3 9660 4909
Email: [email protected]

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/093c81fa-aaed-4023-b77e-1e48f45c7ef5

https://www.globenewswire.com/NewsRoom/AttachmentNg/c5c6a6df-a74a-41f4-b84f-4d4466f9b5f8

CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies
CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies

CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies
CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies

Will Micron's Q1 2026 earnings justify its sky-high valuation? The memory chip giant reports on Dec. 17, with analysts expecting a blockbuster quarter.

Micron Technology (MU +4.61%) reports results for fiscal first-quarter 2026 on Dec. 17. If analyst estimates prove accurate, shareholders might want to break out the champagne -- or at least a celebratory energy drink. You know the drill: Massive computing demand from artificial intelligence (AI) software giants can power massive business results on the hardware side.

Today's Change

(

4.61

%) $

10.45

Current Price

$

237.10

What Wall Street expects from Micron's big day
Wall Street analysts expect the memory chip giant to post earnings of $3.79 per share on revenue of $12.61 billion. That year-over-year growth would make even the most jaded tech investor do a double-take. The earnings estimate points to more than double last year's Q1 earnings of $1.79 per share. Revenue should jump 45% higher, from $8.71 billion.

Recent moves signal confidence in the AI boom's staying power. In November, Micron began shipping its automotive UFS 4.1 solution, doubling bandwidth to 4.2 gigabytes per second (GB/s) to feed data-hungry AI models in next-generation vehicles. Every car is basically a computer nowadays, you know.

More tellingly, Micron announced this week that it's exiting the Crucial consumer business entirely by February 2026. Why abandon a well-known brand? Simply put, they need every ounce of manufacturing capacity for the more lucrative AI server chip market.

Image source: Micron Technology.

About those eye-popping valuation ratios...
Yes, Micron's stock looks pricey at 31 times trailing earnings and a downright comedic 160 times free cash flow. But here's the thing about those ratios -- they can get distorted when a company has recently crawled out of the earnings basement. When your trailing-12-month denominator was barely positive last quarter, even modest improvements create eye-popping multiples.

Demand for high-bandwidth memory shows no signs of cooling, and the memory-chip industry is enjoying skyrocketing unit prices as a result. The supply and-demand economics are working in Micron's favor right now.

So, Micron appears well positioned to deliver another quarter of impressive growth. Tune in on Dec. 17 to see the whole story.

Anders Bylund has positions in Micron Technology. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

AI and Bitcoin pushed Hut 8 upward in the first three quarters of 2025.

Zweig-DiMenna Associates LLC made a significant buy of 508,700 shares of Hut 8 (HUT 0.89%) in Q3 2025. The value of its position increased by approximately $20.92 million.

What happenedZweig-DiMenna Associates disclosed in a November 7, 2025, SEC filing that it increased its holdings in Hut 8 by 508,700 shares during Q3 2025. The post-trade position stood at 707,000 shares, representing a market value of $24.61 million as of September 30, 2025.

What else to knowThe fund reported 94 positions and $1.43 billion in reportable U.S. equity assets. This buy takes Hut 8 to 1.72% of Zweig-DiMenna’s 13F assets under management (AUM), outside the top five fund holdings.

Zweig-DiMenna’s top holdings after the filing: 

AppLovin (APP +1.19%): $81.34 million (6.4% of AUM)Amazon (AMZN +0.16%): $79.37 million (6.2% of AUM)Broadcom (AVGO +2.28%): $69.51 million (5.4% of AUM) GeneDx (WGS 1.85%): $64.89 million (5.1% of AUM)Taiwan Semiconductor Manufacturing (TSM +0.51%): $53.75 million (4.2% of AUM)Company overviewAs of Dec. 5, 2025, Hut 8 shares were priced at $42.43, up 57.0% over the year. It outperformed the S&P 500 by 44.2 percentage points during the same period.

MetricValuePrice$42.43Market capitalization$4.58 billionRevenue (TTM)$178.32 millionNet income (TTM)$205.76 millionData as of market close Dec.5, 2025.

Company snapshotHut 8 operates as a vertically integrated provider of energy infrastructure and digital asset mining. It focuses on Bitcoin (BTC +2.49%) and advanced computing workloads.

The company leverages large-scale data centers to support both cryptocurrency mining and high-performance computing for enterprise clients. It aims to capture value in both digital asset and AI-driven markets.

Hut 8 offers large-scale energy infrastructure, Bitcoin mining, high-performance computing, and artificial intelligence data center services.It generates revenue by designing, building, and operating data centers.It serves enterprise clients and institutions seeking advanced computing and digital asset solutions.Foolish takeHut 8 benefited from two popular investor themes in the first three quarters of 2025: AI and Bitcoin. Indeed, Hut 8 shares soared over 90% in the third quarter alone. This meant that Zweig-DiMenna’s purchase of new shares accounted for only part of its increased exposure. The surging price also pushed up the value of its existing shares.

Hut 8 is one of the top 15 public Bitcoin Treasury companies, per BitcoinTreasuries.net. For much of the year, Bitcoin pushed upward -- in part due to investor optimism about the potential impact of a pro-crypto administration. However, sentiment shifted in October, and crypto prices are now struggling. Hut 8's price has fallen since Zweig-DiMenna’s purchase.

However, Hut 8 is not completely reliant on Bitcoin. Like other Bitcoin miners, the company is positioning itself as a power generator and digital infrastructure firm. Bitcoin is a volatile asset, and mining has become less profitable. Leveraging its energy capabilities to meet the growing demand from AI data centers could give Hut 8 an important alternative revenue stream.

Glossary13F assets under management (AUM): The total value of U.S. equity securities a fund must report quarterly to the Securities and Exchange Commission (SEC).

Position: The amount of a particular security or asset held by an investor or fund.

Stake: The ownership interest or number of shares held in a company by an investor or fund.

Vertically integrated: A business model where a company controls multiple stages of its supply chain or production process.

High performance computing: The use of powerful computers and networks to process complex calculations and large data sets rapidly.

Data center: A facility housing computer systems and infrastructure for storing, processing, and managing data.

Compute-intensive workloads: Tasks or applications that require significant computational power to process large or complex data.

Artificial intelligence (AI) data center services: Data center offerings designed to support AI workloads, such as machine learning and deep learning.

Market value: The total value of a holding, calculated by multiplying the current share price by the number of shares owned.

Outperforming: Achieving a higher return or growth rate than a benchmark or comparable investment.

Digital asset mining: The process of using computing power to validate and record transactions on a blockchain, earning rewards in digital currencies.

TTM: The 12-month period ending with the most recent quarterly report.

"Who's watching?" Netflix asks whenever someone accesses its site. On Friday, it was probably everyone with an interest in business, markets and television.

The key characters that had people hooked were Netflix and Warner Bros. Discovery, which jointly announced that the streaming giant will acquire the latter's film studio and streaming service, HBO Max. The equity deal value is pegged at $72 billion.

Netflix investors did not seem too jazzed about the deal, with shares dropping 2.89% on the sheer size of the transaction.

"Look, the math is going to hurt Netflix for a while. There's no doubt," Rich Greenfield, co-founder of LightShed Partners, told CNBC. "This is expensive," he added.

But if one side is paying a lot, that means the other is receiving a bounty. Indeed, investors cheered the potential Warner Bros. Discovery windfall, sending the stock up 6.3% on the news.

It is not a done deal yet, and faces regulatory scrutiny. U.S. President Donald Trump said he would be involved in the decision, Reuters reported Monday, after a senior official from the Trump administration told CNBC's Eamon Javers on Friday that they viewed the deal with "heavy scepticism."

Despite this initial show of resistance, stranger things have happened in this administration, and the transaction might eventually go through. Should we get ready for Netflix's next blockbuster: "The K-Pop Demon Hunters' Song of Ice and Fire"?

What you need to know todayU.S. stocks had a positive Friday. The S&P 500 had its ninth winning session in 10 and rose 0.3% for the week. Europe's regional Stoxx 600 closed flat. Separately, third-quarter euro zone economic growth was revised upward to 0.3%.

Netflix to buy Warner Bros. Discovery's film and streaming businesses. The total equity value of the deal is $72 billion, announced the two companies Friday. But the transaction could run into regulatory hurdles.

Core inflation in the U.S. cools down. September's core personal consumption expenditures price index was 2.8% on an annual basis, 0.1 percentage point lower than expectations and August's figure. Other numbers were in line with expectations.

A Ukraine peace deal is 'really close.' That's according to Keith Kellogg, the U.S. special envoy for Ukraine, who reportedly said Saturday that there were two key outstanding issues: the future of Ukraine's Donbas region and its Zaporizhzhia nuclear power plant.

[PRO] Goldman Sachs unveils its top five global stocks. The picks are from China, Taiwan, India, Germany and the U.K. — and all offer an upside of at least 70%, according to the bank.

And finally...The history of nuclear energy lies on British soil – does its future?

The U.K. once had more nuclear power stations than the U.S., USSR and France combined. It was a global producer until 1970 but hasn't completed a new reactor since Sizewell B in 1995.

There is ambition to change that. Authorities want a quarter of the U.K.'s power to come from nuclear by 2050. The country is spreading its bets across tried-and-tested large nuclear projects and smaller, next-generation reactors known as small module reactors.

— Tasmin Lockwood

Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall response rate(ORR) in this subgroup of patients80% ORR achieved in newly diagnosed high-risk MDS/CMMLStrong safety profile with no dose-limiting toxicities across all patient cohorts in 103-patient study
ROCKVILLE, Md. and SUZHOU, China, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it presented the latest results from a Phase Ib/II study of Lisaftoclax (APG-2575), a key investigational drug candidate in the Company’s pipeline, in combination with azacitidine (AZA) in patients with newly diagnosed or prior venetoclax–exposed myeloid malignancies in a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting, being held in Orlando, Florida.

The ASH Annual Meeting is one of the largest gatherings of the international hematology community, aggregating cutting-edge scientific research and the latest data on investigational therapies that represent leading scientific and clinical advances in the global hematology field. Once again, Ascentage Pharma’s innovative pipeline has garnered significant attention at this year’s conference, with results from multiple clinical and preclinical studies on three of the Company’s drug candidates (Olverembatinib, Lisaftoclax, and APG-5918) selected for presentations, including an oral report featuring a study on Lisaftoclax.

Data featured in the report further validated the therapeutic potential and favorable tolerability profile of Lisaftoclax in myeloid malignancies, including treatment responses from venetoclax–resistant patients. These results underscore Lisaftoclax’s distinct clinical value that is differentiated from other drugs in the same class.

Lisaftoclax is a novel, orally administered Bcl-2 selective inhibitor developed by Ascentage Pharma. It exerts antitumor effect by selectively blocking the anti-apoptotic protein Bcl-2 and restoring the normal apoptosis process in cancer cells. Lisaftoclax is approved in China for adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy, including Bruton’s tyrosine kinase (BTK) inhibitors. Ascentage Pharma is currently conducting four global registrational Phase III studies to evaluate Lisaftoclax in multiple indications, including CLL/SLL, acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS).

Yifan Zhai, M.D., Ph.D., Chief Medical Officer of Ascentage Pharma, said, “It is our great pleasure to present continued progress in the clinical development of Lisaftoclax in myeloid malignancies such as AML and MDS at the ASH Annual Meeting. These data suggest that this combination regimen has substantial therapeutic potential for the treatment of newly diagnosed or venetoclax–exposed patients. We hope that Lisaftoclax will bring a breakthrough to the clinical management of myeloid malignancies. Fulfilling our mission of addressing unmet clinical needs in China and around the world, we will strive to accelerate our clinical programs to bring more safe and effective therapies to patients as soon as possible.”

Highlights of the data this study reported at ASH 2025 are as below:

Results of the APG2575AU101 study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients with newly diagnosed (ND) or prior venetoclax–exposed myeloid malignancies
Format: Poster Presentation
Abstract#: 1641
Session: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster I
Time: Saturday, December 6, 2025; 5:30 PM – 7:30 PM EST
First Author: Dr. Tapan Kadia, Department of Leukemia, The University of Texas MD Anderson Cancer Center
Presenter: Dr. Tapan Kadia, Department of Leukemia, The University of Texas MD Anderson Cancer Center
Highlights:
Background:

AML and MDS have poor prognoses. Venetoclax plus hypomethylating agent AZA is approved for certain patients with AML, but many patients are unable to benefit from treatment because of failure to respond or intolerance. Even patients who achieve complete responses (CRs) in early treatment eventually experience relapse.Lisaftoclax, a novel, oral small-molecular Bcl-2 inhibitor, has shown enhanced treatment responses when combined with AZA in preclinical and clinical studies. Introduction:

This was a phase Ib/II study (NCT04964518) designed to evaluate the efficacy and safety of lisaftoclax in combination with AZA in patients with ND or relapsed/refractory AML, mixed-phenotype acute leukemia (MPAL), chronic myelomonocytic leukemia (CMML), or higher-risk (HR) MDS. The first part of this study was the dose-escalation phase and the second part was the dose-expansion phase.As of July 1, 2025, 103 patients were enrolled, including 63 patients with AML/MPAL (of whom 56 had relapsed/refractory diseases) and 40 patients with HR MDS/CMML (of whom 25 had relapsed/refractory diseases). Efficacy Results:

In the 44 evaluable patients with R/R AML/MPAL, the ORR was 43.2%, and the CR rate was 31.8% (14/44). In the 22 evaluable patients with venetoclax–exposed R/R AML/MPAL, the ORR was 31.8% (7/22), and the CR rate was 22.7% (5/22).In the 15 evaluable patients with ND HR MDS/CMML, the ORR was 80.0%, including 6 (40.0%) patients who achieved a CR, and 6 (40.0%) who achieved a marrow CR (mCR).Median overall survival (OS) values for patients with R/R AML/MPAL or R/R HR MDS/CMML were 7.6 months and 11.3 months, respectively.The median OS was 6.3 months in patients with ND AML/MPAL and was not reached in patients with ND HR MDS/CMML. Safety Results: No dose-limiting toxicities (DLTs) were reported in part one for dose-escalation or part two for dose-expansion. Common grade ≥3 treatment-emergent adverse events (TEAEs) included neutropenia (41.7%), febrile neutropenia (35.0%), thrombocytopenia (26.2%), and anemia (17.5%).

Conclusion: These preliminary clinical data show that the combination regimen of lisaftoclax plus AZA holds promise in overcoming venetoclax resistance, therefore potentially offering a new treatment option to patients with AML/HR MDS.

* Lisaftoclax, Olverembatinib and APG-5918 are currently under investigation and have not yet been approved by the FDA in the U.S.

About Ascentage Pharma
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, as well as next-generation kinase inhibitors.

The lead asset, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. All indications are covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of Olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL and SDH-deficient GIST patients.

The Company’s second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax is being commercialized in China following National Medical Products Administration (NMPA) approval for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with acute myeloid leukemia ( AML); and the GLORA-4 study in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR MDS), a study that was simultaneously cleared by the U.S. FDA, the EMA of the EU, and China CDE.

Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/

Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition.

These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Special note regarding forward-looking statements and industry data” in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed “Forward-looking Statements” and “Risk Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company’s management.

As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Investor Relations:
Stella Yang
Ascentage Pharma
[email protected]
+1 (301) 792-6286

Stephanie Carrington
ICR Healthcare
[email protected]
+1 (646) 277-1282

Media Relations:
Sean Leous
ICR Healthcare
[email protected]
+1 (646) 866-4012

Oil held steady in the early Asian trade. This could be due to a possible oil supply glut and stalled Ukraine-Russia peace talks, said UOB.